Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | FNTA | P49354 | 6/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1668235 | 0.86 | KDM4E (0.53) | KDM4EALDH1A1KCNH2GPR119PPARD | |
| SCHEMBL12198375 | 0.82 | KDM4E (0.43) | KDM4EALDH1A1FNTAPGGT1BPPARD | |
| SCHEMBL1668410 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1KCNH2GPR119CYP2D6 | |
| SCHEMBL1668706 | 0.79 | KDM4E (0.45) | KDM4EALDH1A1KCNH2GPR119FNTA | |
| SCHEMBL1668348 | 0.79 | KDM4E (0.45) | KDM4EALDH1A1KCNH2GPR119FNTA | |
| SCHEMBL1668529 | 0.78 | KDM4E (0.51) | KDM4EALDH1A1KCNH2GPR119PPARD | |
| SCHEMBL1668615 | 0.77 | KDM4E (0.44) | KDM4EALDH1A1KCNH2GPR119CYP2D6 | |
| SCHEMBL12198370 | 0.75 | ALDH1A1 (0.51) | KDM4EALDH1A1PPARDPPARATACR1 | |
| SCHEMBL1668262 | 0.75 | KDM4E (0.48) | KDM4EALDH1A1KCNH2GPR119CYP2D6 | |
| SCHEMBL12198321 | 0.73 | KDM4E (0.52) | KDM4EALDH1A1KCNH2GPR119CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575168-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2013-11-05 | — | — | US | claimed |
| EP-2486033-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2012-08-15 | — | — | EP | claimed |
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-06 | — | — | US | claimed |
| WO-2011044001-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-04-14 | — | — | WO | claimed |
| US-8575168-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2013-11-05 | — | — | US | disclosed |
| US-8575168-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2013-11-05 | — | — | US | disclosed |
| EP-2486033-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2012-08-15 | — | — | EP | disclosed |
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-06 | — | — | US | disclosed |
| WO-2011044001-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | KDM4E 3454/4885ALDH1A1 2341/4885KCNH2 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.